IL274777A - Cladribine regimen for treating progressive forms of multiple sclerosis - Google Patents

Cladribine regimen for treating progressive forms of multiple sclerosis

Info

Publication number
IL274777A
IL274777A IL274777A IL27477720A IL274777A IL 274777 A IL274777 A IL 274777A IL 274777 A IL274777 A IL 274777A IL 27477720 A IL27477720 A IL 27477720A IL 274777 A IL274777 A IL 274777A
Authority
IL
Israel
Prior art keywords
multiple sclerosis
progressive forms
treating progressive
cladribine
regimen
Prior art date
Application number
IL274777A
Other languages
Hebrew (he)
Inventor
Matthias Dotzauer
Fernando Dangond
Original Assignee
Merck Patent Gmbh
Matthias Dotzauer
Fernando Dangond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64457023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL274777(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh, Matthias Dotzauer, Fernando Dangond filed Critical Merck Patent Gmbh
Publication of IL274777A publication Critical patent/IL274777A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
IL274777A 2017-11-24 2020-05-19 Cladribine regimen for treating progressive forms of multiple sclerosis IL274777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590442P 2017-11-24 2017-11-24
PCT/EP2018/082434 WO2019101960A1 (en) 2017-11-24 2018-11-23 Cladribine regimen for use intreating progressive forms of multiple sclerosis

Publications (1)

Publication Number Publication Date
IL274777A true IL274777A (en) 2020-07-30

Family

ID=64457023

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274777A IL274777A (en) 2017-11-24 2020-05-19 Cladribine regimen for treating progressive forms of multiple sclerosis

Country Status (15)

Country Link
US (3) US10849919B2 (en)
EP (1) EP3713582A1 (en)
JP (1) JP2021504363A (en)
KR (1) KR20200090824A (en)
CN (1) CN111356460A (en)
AR (1) AR113906A1 (en)
AU (1) AU2018372007A1 (en)
BR (1) BR112020010282A2 (en)
CA (1) CA3083328A1 (en)
EA (1) EA202091253A1 (en)
IL (1) IL274777A (en)
MX (2) MX2020005266A (en)
SG (1) SG11202004772RA (en)
TW (1) TW201936199A (en)
WO (1) WO2019101960A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002843A (en) * 2020-09-10 2023-03-31 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CZ194297A3 (en) 1994-12-22 1997-10-15 Ortho Pharma Corp Solution of 2-chloro-2-deoxyadenosine in water
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
AU2003275267A1 (en) 2002-09-25 2004-04-19 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
KR101129816B1 (en) 2003-03-28 2012-03-26 아레스 트레이딩 에스.아. Oral formulations of cladribine
CN101912615B (en) 2003-03-28 2013-03-27 阿莱斯贸易有限公司 Cladribine formulations for improved oral and transmucosal delivery
SI2805723T1 (en) * 2004-12-22 2018-02-28 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US9925151B2 (en) * 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
WO2017035357A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders

Also Published As

Publication number Publication date
CA3083328A1 (en) 2019-05-31
TW201936199A (en) 2019-09-16
EA202091253A1 (en) 2020-09-29
BR112020010282A2 (en) 2020-11-17
CN111356460A (en) 2020-06-30
EP3713582A1 (en) 2020-09-30
US20190167707A1 (en) 2019-06-06
AU2018372007A1 (en) 2020-07-09
JP2021504363A (en) 2021-02-15
WO2019101960A1 (en) 2019-05-31
US20230021880A1 (en) 2023-01-26
AR113906A1 (en) 2020-06-24
US10849919B2 (en) 2020-12-01
MX2020005266A (en) 2020-09-18
MX2023007405A (en) 2023-06-29
KR20200090824A (en) 2020-07-29
US20210169912A1 (en) 2021-06-10
SG11202004772RA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
HUE041885T2 (en) Adaptive cross component residual prediction
HK1253743A1 (en) Method of treating multiple sclerosis employing a lsd1-inhibitor
GB201517879D0 (en) Method of deposition
IL252296A0 (en) Methods of treating multiple sclerosis
HK1252996A1 (en) Methods for the treatment of epilepsy
GB201517128D0 (en) Abrasive blast modification of surfaces
EP3322554C0 (en) Method for the additive manufacture of metallic components
HK1246655A1 (en) Methods of treating infertility
SG10201602315RA (en) Method of dividing wafer
HK1251965A1 (en) Methods for treating epilepsy
IL272092A (en) Methods of treating behavior alterations
IL265259A (en) Treatment of multiple sclerosis with chs-131
GB201401465D0 (en) Use of cladribine for treating autoimmune inflammatory disease
GB201509082D0 (en) Coating process
IL255498A (en) Treatment of pruritus
IL254619A0 (en) Biotin for treating amyotrophic lateral sclerosis
IL274777A (en) Cladribine regimen for treating progressive forms of multiple sclerosis
IL269555A (en) Glatiramer depot systems for treating progressive forms of multiple sclerosis
IL269681A (en) New methods for the treatment of multiple sclerosis
HK1257072A1 (en) Method for treating multiple sclerosis
SG11201710199PA (en) Methods of treating multiple sclerosis
GB201814356D0 (en) Methods of detergents
PT3141360T (en) Apparatus for applying studs
ZA201707232B (en) Treatment of a hydrocarbon component
IL257768A (en) Processes for regeneration of organocations